Adamis Pharma changes name to DMK Pharmaceuticals, ticker to DMK, pivots to substance use disorders

DMK PHARMACEUTICALS Corp

Adamis Pharmaceuticals renamed DMK Pharmaceuticals effective September 6, 2023; new Nasdaq ticker 'DMK' begins September 8, 2023.
Strategic focus shifts to small-molecule therapies for substance use disorders, including opioid overdose treatment ZIMHI® and clinical compound DPI-125.
DPI-125 targets opioid use disorder and moderate-to-severe pain; company expects milestones by end 2024 including transdermal delivery, safety study, and abuse liability study.
No stockholder vote required; CUSIP unchanged; no impact on existing shareholder rights.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

DMK PHARMACEUTICALS Corp: Company changed its corporate name from Adamis Pharmaceuticals Corporation to DMK Pharmaceuticals Corporation via a certificate of amendment to the restated certificate of incorporation (effective 2023-09-06).

Change: charter amendment
Effective: 2023-09-06

Exact text from the filing

Effective September 6, 2023, Adamis Pharmaceuticals Corporation (the “Company”) changed its corporate name to DMK Pharmaceuticals Corporation (the “Name Change”) pursuant to a certificate of amendment to the Company’s restated certificate of incorporation (the “Charter Amendment”) filed with the Secretary of State of Delaware.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

DMK PHARMACEUTICALS Corp: Amended and restated its Amended and Restated Bylaws to reflect the name change to DMK Pharmaceuticals Corporation (effective 2023-09-06).

Change: bylaw amendment
Effective: 2023-09-06

Exact text from the filing

On the effective date of the Name Change the Company also amended and restated its Amended and Restated Bylaws (the “Amended and Restated Bylaws”), to reflect the Name Change.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001387131-23-010995

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.